TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16815137

Group type: EXPERIMENTAL
Intervention: 100/50 microg of fluticasone propionate/salmeterol administered through a Diskus inhaler twice daily for 24 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: 250 microg of fluticasone propionate administered through a Diskus inhaler twice daily for 24 weeks
Number of subjects: 88
Study: 15178953

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11059698

Group type: EXPERIMENTAL
Intervention: Auditory brain stem responses, transient evoked otoacoustic emissions, and distortion product otoacoustic emissions as hearing-screening tools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neonatal test battery including measures of middle-ear function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monthly reports for monitoring subject enrollment and data integrity checks
Number of subjects: 0
Study: 9103129

Group type: EXPERIMENTAL
Intervention: Propafenone (500 mg oral dose)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 8470978

Group type: EXPERIMENTAL
Intervention: Diclofenac (0.1%) drops
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 53
Study: 3542826

Group type: EXPERIMENTAL
Intervention: Isotonic amino acid solution
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard fluid therapy
Number of subjects: 30
Study: 29703978

Group type: EXPERIMENTAL
Intervention: MR Fingerprinting using slice-interleaved echo-planar imaging (MRF-EPI) with 32 slices acquired in 3:36 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phantom scans for validation
Number of subjects: 0
Study: 27425563

Group type: EXPERIMENTAL
Intervention: School readiness intervention
Number of subjects: 209
Study: 23857798

Group type: EXPERIMENTAL
Intervention: Total 25(OH)D levels
Number of subjects: 2073

Group type: EXPERIMENTAL
Intervention: Free 25(OH)D levels
Number of subjects: 2073

Group type: EXPERIMENTAL
Intervention: Total 25(OH)D levels (adjusted for covariates)
Number of subjects: 2073
Study: 22402738

Group type: EXPERIMENTAL
Intervention: Better Pittsburgh Sleep Quality Index (PSQI) Global Score
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Sleeping >7 h/night
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Worse PSQI Global Score at 6 months
Number of subjects: 245
Study: 20142414

Group type: EXPERIMENTAL
Intervention: Strengthening Families Program: For Parents and Youth 10-14 (SFP)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Family Matters (FM)
Number of subjects: 381
Study: 18484981

Group type: EXPERIMENTAL
Intervention: Almotriptan 25 mg
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Almotriptan 6.25 mg
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Almotriptan (all doses)
Number of subjects: 866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866
Study: 16404943

Group type: EXPERIMENTAL
Intervention: Antioxidants - vitamins E and ascorbic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 0
Study: 12622501

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg disintegrating tablets, administered orally every 12 hours for 3 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo, administered orally every 12 hours for 3 days
Number of subjects: 96
Study: 12206008

Group type: EXPERIMENTAL
Intervention: Panax notoginseng saponins (PNS) + isovolumic haemodilution (IHD)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Panax notoginseng saponins (PNS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Isovolumic haemodilution (IHD)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study: 9552709

Group type: EXPERIMENTAL
Intervention: Azithromycin (3-day regimen)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Co-amoxiclav (10-day regimen)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 144
Study: 8452187

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg oral
Number of subjects: 905

Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg intramuscular
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 905

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 905
Study: 3334206

Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 103
Study: 29710741

Group type: EXPERIMENTAL
Intervention: Microprocessor-controlled prosthetic knee (i-KNEE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-microprocessor-controlled prosthetic knee (NMPK)
Number of subjects: 12
Study: 27677547

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 281
Study: 25782898

Group type: EXPERIMENTAL
Intervention: Universal gowning/gloving
Number of subjects: 348

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 348
Study: 22929568

Group type: COMPARATOR
Intervention: abciximab infusion with the ClearWay coronary catheter (C)
Number of subjects: 128

Group type: COMPARATOR
Intervention: standard abciximab infusion (A)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: thrombectomy followed by abciximab infusion with the ClearWay catheter (T+C)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: thrombectomy followed by standard abciximab infusion (T+A)
Number of subjects: 128
Study: 20872019

Group type: EXPERIMENTAL
Intervention: Multiport (MP) training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single-site access (SSA) training
Number of subjects: 40

Group type: COMPARATOR
Intervention: MP training on SSA setup after crossover
Number of subjects: 40

Group type: COMPARATOR
Intervention: SSA training on MP setup after crossover
Number of subjects: 40
Study: 18720328

Group type: EXPERIMENTAL
Intervention: Picrotoxin suppositories at 0.001 g three times a week
Number of subjects: 41

Group type: COMPARATOR
Intervention: Betahistine 3x12 mg
Number of subjects: 41
Study: 17361524

Group type: EXPERIMENTAL
Intervention: Chibixiao Recipe (CBX) in combination with minocycline and spironolactone
Number of subjects: 68

Group type: COMPARATOR
Intervention: Minocycline and spironolactone (control group)
Number of subjects: 68
Study: 14585770

Group type: EXPERIMENTAL
Intervention: Cluster randomized controlled trials (CRCTs)
Number of subjects: 51
Study: 10910241

Group type: EXPERIMENTAL
Intervention: Omentoplasty (Group A)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No omentoplasty (Group B)
Number of subjects: 112
Study: 8910149

Group type: EXPERIMENTAL
Intervention: Albunex (2 to 8 mL injected before and after coronary revascularization)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Albunex (average total dose of 19 mL +/- 4, 0.25 mL/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no Albunex)
Number of subjects: 32
Study: 1725447

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg p.o. once daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6617205

Group type: EXPERIMENTAL
Intervention: i.m. norethisterone enanthate (NET‐e) 200 mg every two months
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral combination of 1-norgestrel 150 micrograms and ethinyl estradiol 30 micrograms
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-medicated IUD (control group)
Number of subjects: 21
Study: 31919403

Group type: EXPERIMENTAL
Intervention: Patient-derived xenograft (PDX) models
Number of subjects: 0
Study: 30719589

Group type: EXPERIMENTAL
Intervention: Abaloparatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 0
Study: 29336128

Group type: EXPERIMENTAL
Intervention: PRP-enriched gelfoam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional gelfoam
Number of subjects: 24
Study: 26674292

Group type: EXPERIMENTAL
Intervention: Spa treatment (procedures and drinking cure)
Number of subjects: 96
Study: 24703722

Group type: EXPERIMENTAL
Intervention: Itolizumab arm A (4-week loading dose of 0.4 mg/kg/wk followed by 1.6 mg/kg every 2 weeks)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Itolizumab arm B (1.6 mg/kg every 2 weeks)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Itolizumab arm A
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Itolizumab arm B
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: All treatment arms (A, B, placebo)
Number of subjects: 225
Study: 22189537

Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) vaccination immediately at first health center contact
Number of subjects: 105
Study: 19775046

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg (Group IA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg (Group IB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol (Group IIA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etomidate (Group IIB)
Number of subjects: 20
Study: 17523339

Group type: EXPERIMENTAL
Intervention: D4 gastrectomy
Number of subjects: 270

Group type: COMPARATOR
Intervention: D2 gastrectomy
Number of subjects: 270
Study: 15543160

Group type: EXPERIMENTAL
Intervention: Dietary counselling during 2 months weight reduction with very-low-energy-diet and 6 months weight maintenance programme including physical activity counselling.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dietary counselling during the study period.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dietary counselling and assessments during the study.
Number of subjects: 36
Study: 11148432

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9517944

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg every 12 h)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily)
Number of subjects: 34
Study: 16892732

Group type: EXPERIMENTAL
Intervention: Prednisolone (30mg once daily in the morning)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sustained-release theophylline (600-800mg per day in b.i.d. dosage)
Number of subjects: 20
Study: 2195106

Group type: EXPERIMENTAL
Intervention: Branched chain enriched amino acid mixture (1 g/kg per day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Isocaloric glucose infusion
Number of subjects: 65
Study: 7377640

Group type: EXPERIMENTAL
Intervention: Sustained release theophylline tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short acting theophylline tablets
Number of subjects: 0
Study: 31689457

Group type: EXPERIMENTAL
Intervention: ctDCS-atDCS
Number of subjects: 11

Group type: COMPARATOR
Intervention: sham-atDCS
Number of subjects: 11
Study: 31416692

Group type: EXPERIMENTAL
Intervention: CTH522 adjuvanted with CAF01 liposomes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CTH522 adjuvanted with aluminium hydroxide
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 35
Study: 28625451

Group type: EXPERIMENTAL
Intervention: 5% dextrose
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study: 26253568

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Plasma renin
Number of subjects: 346
Study: 24476905

Group type: EXPERIMENTAL
Intervention: C2 nerve root transection
Number of subjects: 28

Group type: COMPARATOR
Intervention: C2 nerve root preservation
Number of subjects: 28
Study: 21762554

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 406

Group type: COMPARATOR
Intervention: Standard medical therapy (control)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 406
Study: 20621273

Group type: EXPERIMENTAL
Intervention: Usual Care plus Music Intervention (MI)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 53
Study: 17686624

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate combined with salmeterol
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Fluticasone propionate
Number of subjects: 1242
Study: 15871754

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) daily for 3 days for intervals of 8, 6, and 4 hours, plus standard therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 25
Study: 12475399

Group type: EXPERIMENTAL
Intervention: PR + IM
Number of subjects: 76

Group type: COMPARATOR
Intervention: PR alone
Number of subjects: 76
Study: 10487134

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium (Group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.015 mg/kg pancuronium (Group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg rocuronium (Group III)
Number of subjects: 30
Study: 8929939

Group type: EXPERIMENTAL
Intervention: Long-term treatment (duration not specified, but retention for more than three months is noted)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Client characteristics (gender, education, age, psychiatric morbidity, drug of choice, attendance at AA/NA meetings, prior treatment histories)
Number of subjects: 0
Study: 1973939

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 63806

Group type: EXPERIMENTAL
Intervention: Epidural analgesia during surgery
Number of subjects: 16

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 16
Study: 29253208

Group type: EXPERIMENTAL
Intervention: Graphic antismoking poster placed near the tobacco power wall: Yes
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Graphic antismoking poster placed near the cash register: Yes
Number of subjects: 441

Group type: COMPARATOR
Intervention: Graphic antismoking poster placed near the tobacco power wall: No
Number of subjects: 441

Group type: COMPARATOR
Intervention: Graphic antismoking poster placed near the cash register: No
Number of subjects: 441
Study: 29228763

Group type: EXPERIMENTAL
Intervention: K‐0184
Number of subjects: 96

Group type: COMPARATOR
Intervention: Positive control (no treatment)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Shield Force Plus
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Xeno Select
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adhese Universal
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: OptiBond All‐In‐One
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 96
Study: 24594536

Group type: EXPERIMENTAL
Intervention: Classical light music (n=16)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Popular music (n=17)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Quiet environment (control group, n=16)
Number of subjects: 49
Study: 23265995

Group type: EXPERIMENTAL
Intervention: Amoxicillin (1 g three times daily for 7 days)
Number of subjects: 2061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2061
Study: 21300709

Group type: EXPERIMENTAL
Intervention: Automated office blood pressure
Number of subjects: 555

Group type: COMPARATOR
Intervention: Manual office blood pressure
Number of subjects: 555
Study: 19318384

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (target blood glucose range of 81 to 108 mg/dL)
Number of subjects: 6104

Group type: COMPARATOR
Intervention: Conventional glucose control (target blood glucose of 180 mg/dL or less)
Number of subjects: 6104

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 6104

Group type: COMPARATOR
Intervention: Conventional glucose control
Number of subjects: 6104
Study: 17089240

Group type: COMPARATOR
Intervention: RVA pacing
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: RVOT pacing
Number of subjects: 27
Study: 15270803

Group type: EXPERIMENTAL
Intervention: Pulsed-dose electrical stimulation (50 micro amps) through silver-plated nylon-dacron stocking electrodes for 8 hours a night for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with identical stockings receiving insignificant current (5 micro amps)
Number of subjects: 30
Study: 11772239

Group type: EXPERIMENTAL
Intervention: Novel treatments targeting specific steps in the disease process, including mycophenolate mofetil and adenosine analogues.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoablative chemotherapy with or without haematopoietic stem cell rescue.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking co-stimulatory molecules (e.g., CD40 ligand, CTLA4-Ig).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking IL-10.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treating with DNase or blocking C5 in the complement cascade.
Number of subjects: 0
Study: 9204616

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Linton‐Michel tube (LM tube)
Number of subjects: 37
Study: 7619743

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 0
Study: 2912716

Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 1094253

Group type: EXPERIMENTAL
Intervention: Sequential therapy with conjugated Estrogens (Presomen) 1.25 mg/day from day 5 to 24 of the cycle, and synthetic Gestagen 6 mg/day for the last 5, 7, or 10 days of the cycle
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sequential therapy with conjugated Estrogens (Presomen) and synthetic Gestagen
Number of subjects: 85
Study: 31230024

Group type: EXPERIMENTAL
Intervention: Nurse-led triage
Number of subjects: 200

Group type: COMPARATOR
Intervention: GP-led triage
Number of subjects: 200
Study: 29245244

Group type: EXPERIMENTAL
Intervention: Joint mobilization manipulation treatment once a day and regular training twice a day for a month
Number of subjects: 120

Group type: COMPARATOR
Intervention: Physical therapy once a day and regular training twice a day for a month
Number of subjects: 120

Group type: COMPARATOR
Intervention: Regular training twice a day for a month
Number of subjects: 120
Study: 26343780

Group type: EXPERIMENTAL
Intervention: Sodium supplementation (3.0 g/d)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (2.8 g/d)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 23168298

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (25 μg, 1000 IU)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Vitamin D2 (25 μg, 1000 IU)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 21701326

Group type: EXPERIMENTAL
Intervention: PlasmaBlade
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional electrosurgery
Number of subjects: 20
Study: 19225210

Group type: EXPERIMENTAL
Intervention: Benidipine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (Normal subjects)
Number of subjects: 25
Study: 16924031

Group type: EXPERIMENTAL
Intervention: Continuous HT users
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Irregular HT users
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-HT users
Number of subjects: 60
Study: 15650459

Group type: EXPERIMENTAL
Intervention: Patient-specific dendritic cell vaccine with GM-CSF, administered subcutaneously once a week for 3 weeks, then once a month for 5 months.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patient-specific dendritic cell vaccine with GM-CSF
Number of subjects: 20
Study: 11302277

Group type: EXPERIMENTAL
Intervention: Motivational enhancement telephone intervention and self-help workbook
Number of subjects: 102

Group type: COMPARATOR
Intervention: Self-help workbook only
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 102
Study: 9431864

Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy patients
Number of subjects: 12
Study: 8513655

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Naringin solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study: 17171908

Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Diazepam (0.4 mg/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both agents (Etomidate and Diazepam)
Number of subjects: 11
Study: 30273270

Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study: 27808553

Group type: EXPERIMENTAL
Intervention: Traffic signs that are representative of their meaning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traffic signs that are least representative of their meaning
Number of subjects: 0
Study: 25539966

Group type: EXPERIMENTAL
Intervention: SHARE plus HIV services
Number of subjects: 11448

Group type: COMPARATOR
Intervention: HIV services only
Number of subjects: 11448
Study: 23725518

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F extract (TwHF) 120 mg/day for 3 months, then 60 mg/day for 3 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Valsartan 160 mg/day for 6 months
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: TwHF extract
Number of subjects: 65
Study: 20943716

Group type: EXPERIMENTAL
Intervention: Intra-articular steroid injection
Number of subjects: 26

Group type: COMPARATOR
Intervention: Suprascapular nerve block
Number of subjects: 26
Study: 18328360

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 95